Acute myelogenous leukaemia (AML) is a malignant disease of the bone marrow in which hematopoietic precursors are arrested in an early stage of development. Data were available for 3,220 patients (63% women) from 40 Italian centers. Follow-up (mean ± SD) was 49 ± 29 months (range 12-140 months). We observed 30 cases of AML (incidence 0.93% [95% confidence interval 0.60%-1.26%]). The mean cumulative dose was higher in patients with AML (78 vs 65 mg/m(2), p = 0.028).
Symptoms: The underlying pathophysiology in AML consists of a maturational arrest of bone marrow cells in the earliest stages of development. The mechanism of this arrest is under study, but in many cases, it involves the activation of abnormal genes through chromosomal translocations and other genetic abnormalities.his developmental arrest results in 2 disease processes. First, the production of normal blood cells markedly decreases, which results in varying degrees of anaemia, thrombocytopenia, and neutropenia.
Meeting a medical practitioner; Patients with AML should be instructed to call their healthcare providers immediately if they are febrile or have signs of bleeding. For patient education resources, see the Blood and Lymphatic System Center and the Skin, Hair, and Nails Center, as well as Leukemia and Bruises.Current standard chemotherapy regimens cure only a minority of patients with AML. As a result, all patients should be evaluated for entry into well-designed clinical trials. If a clinical trial is not available, the patient can be treated with standard therapy. For consolidation chemotherapy or for the management of toxic effects of chemotherapy, readmission is required.